HeraMED Ltd
HMD
Company Profile
Business description
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.
Contact
201, 697 Burke Road
Suite 4
CamberwellVIC3124
AUST: +61 272511888
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
Shockwaves from Monday's AI stock panic in the US were largely confined to two ASX industries.
video
What does a weak Aussie dollar mean for investors?
Morningstar Investment Management's Chief Investment Officer for Asia Pacific weighs in on the weak Aussie dollar and what this could mean for investors.
stocks
AI stock rout: The US selloff in 4 charts
Worries about Western AI dominance permeated the markets, with Nvidia stock plunging 17% alongside other chipmakers, utilities, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.90 | 45.20 | 0.52% |
| CAC 40 | 7,941.64 | 69.16 | 0.88% |
| DAX 40 | 21,727.20 | 89.67 | 0.41% |
| Dow JONES (US) | 44,984.83 | 271.31 | 0.61% |
| FTSE 100 | 8,646.88 | 89.07 | 1.04% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,713.09 | 80.77 | 0.41% |
| Nikkei 225 | 39,513.97 | 99.19 | 0.25% |
| NZX 50 Index | 12,928.38 | 74.66 | -0.57% |
| S&P 500 | 6,077.44 | 38.13 | 0.63% |
| S&P/ASX 200 | 8,493.70 | 46.70 | 0.55% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |